The Medicines and Healthcare products Regulatory Agency (MHRA) announced on 8 July 2026 the approval of nerandomilast, marketed as Jascayd, for the treatment of adult patients living with Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF). This development offers a new therapeutic avenue for individuals grappling with these chronic and often life-limiting lung conditions.
IPF and PPF are characterised by the gradual scarring of lung tissue, a process that progressively impairs lung function and makes breathing increasingly difficult. The active ingredient in Jascayd, nerandomilast, is designed to modulate the immune system and diminish the fibrotic scarring within the lungs, aiming to slow the progression of these diseases.
Patients will be able to access nerandomilast only through a prescription from their doctor. The recommended dosage is an 18mg tablet, to be taken orally twice a day, as directed by a healthcare professional. As with any new medication, patients are encouraged to adhere strictly to their prescribed regimen and to discuss any concerns with their doctor or pharmacist.
Julian Beach, MHRA Executive Director of Healthcare Quality and Access, commented on the approval, stating that nerandomilast represents a new treatment option for adults with IPF and PPF. He emphasised the MHRA's commitment to ensuring patients have access to safe and effective medicines, particularly where there is a significant unmet clinical need. The agency also confirmed that the safety and effectiveness of nerandomilast will remain under continuous review.
Common side effects associated with nerandomilast, affecting more than 1 in 10 people, include diarrhoea and weight loss. Patients experiencing any suspected adverse reactions are advised to consult their doctor, pharmacist, or nurse and to report these effects directly to the MHRA's Yellow Card scheme. This scheme allows for the monitoring of medicinal product safety in the UK and can be accessed via their website or dedicated app.
According to NHS data, Idiopathic Pulmonary Fibrosis affects thousands of people across the UK, with incidence increasing with age. While there is no cure for IPF, treatments aim to slow its progression and manage symptoms. The introduction of nerandomilast adds to the existing treatment landscape, potentially offering more options for patients and their clinicians in managing these complex conditions.